FDA inspection

SGS Institut Fresenius Berlin GmbH & Co. KG: FDA inspection ending Sep 21, 2006

FDA inspection 444597 · No Action Indicated (NAI) · Berlin

Key facts

Inspection ID 444597
Firm SGS Institut Fresenius Berlin GmbH & Co. KG
FEI number 3004908885
Address Tegeler Weg 33
City Berlin
Fiscal year 2006
Inspection end date Sep 21, 2006
Classification No Action Indicated (NAI)
Project area Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation
Product type Drugs

At a glance

  • None Citations
  • None Posted citations
  • No Warning letter followed
  • Yes Form FDA 483 issued
  • No Establishment inspection report (EIR) exists
  • 1–9 Inspections at this FEI

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About FDA inspections

FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.

Source: U.S. Food and Drug Administration (FDA), inspection classification data

Browse all FDA inspections